3-drug Combo Improves Survival Period for Bowel Cancer Patients
A targeted three-drug combination therapy resulted in a median
overall survival of nine months for patients with advanced bowel cancer
compared to 5.4 months for current standard-of-care treatment, showed
the results of a phase-3 clinical trial.
The data suggested that the three-drug combination, encorafenib, binimetinib and cetuximab, should replace chemotherapy for patients with metastatic colorectal cancer who have a BRAF gene flaw. Metastatic cancer can spread from one organ to another.
BRAF mutations are estimated to occur in up to 15 per cent of patients with metastatic colorectal cancer, with V600E being the most common BRAF mutation and representing a poor prognosis for these patients.
"This study builds on a decade of research into the tumour biology of BRAF-mutated colorectal cancer, and reflects a rationale combination to address the vulnerabilities unique to this tumour," said principal investigator.
"We are encouraged to see a meaningful improvement in outcomes with this new regimen for our patients," he added.
The international study was a multi-institutional collaboration with over 200 centres worldwide.
The clinical trial involved 665 metastatic colorectal cancer patients with BRAF mutation.
The data suggested that the three-drug combination, encorafenib, binimetinib and cetuximab, should replace chemotherapy for patients with metastatic colorectal cancer who have a BRAF gene flaw. Metastatic cancer can spread from one organ to another.
BRAF mutations are estimated to occur in up to 15 per cent of patients with metastatic colorectal cancer, with V600E being the most common BRAF mutation and representing a poor prognosis for these patients.
"This study builds on a decade of research into the tumour biology of BRAF-mutated colorectal cancer, and reflects a rationale combination to address the vulnerabilities unique to this tumour," said principal investigator.
"We are encouraged to see a meaningful improvement in outcomes with this new regimen for our patients," he added.
The international study was a multi-institutional collaboration with over 200 centres worldwide.
The clinical trial involved 665 metastatic colorectal cancer patients with BRAF mutation.
THIS IS ONLY FOR INFORMATION, ALWAYS CONSULT YOU PHYSICIAN BEFORE
HAVING ANY PARTICULAR FOOD/ MEDICATION/EXERCISE/OTHER REMEDIES.
PS-
THOSE INTERESTED IN
RECIPES ARE FREE TO VIEW MY BLOG-
https://gseasyrecipes.blogspot.com/
FOR INFO ABOUT KNEE
REPLACEMENT, YOU CAN VIEW MY BLOG-
https:// kneereplacement-stickclub.blogspot.com/
FOR
CROCHET DESIGNS
https://gscrochetdesigns.blogspot.com
Labels: 3 drug combo, advanced, bowel cancer, BRAF gene mutations, colorectal cancer, metastatic, replace chemo, survival, Targeted Therapy
0 Comments:
Post a Comment
<< Home